Literature DB >> 17569884

A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease.

May M Luke1, John P Kane, Dongming M Liu, Charles M Rowland, Dov Shiffman, June Cassano, Joseph J Catanese, Clive R Pullinger, Diane U Leong, Andre R Arellano, Carmen H Tong, Irina Movsesyan, Josephina Naya-Vigne, Curtis Noordhof, Nicole T Feric, Mary J Malloy, Eric J Topol, Marlys L Koschinsky, James J Devlin, Stephen G Ellis.   

Abstract

OBJECTIVES: The purpose of this study was to identify genetic variants associated with severe coronary artery disease (CAD). METHODS AND
RESULTS: We used 3 case-control studies of white subjects whose severity of CAD was assessed by angiography. The first 2 studies were used to generate hypotheses that were then tested in the third study. We tested 12,077 putative functional single nucleotide polymorphisms (SNPs) in Study 1 (781 cases, 603 controls) and identified 302 SNPs nominally associated with severe CAD. Testing these 302 SNPs in Study 2 (471 cases, 298 controls), we found 5 (in LPA, CALM1, HAP1, AP3B1, and ABCG2) were nominally associated with severe CAD and had the same risk alleles in both studies. We then tested these 5 SNPs in Study 3 (554 cases, 373 controls). We found 1 SNP that was associated with severe CAD: LPA I4399M (rs3798220). LPA encodes apolipoprotein(a), a component of lipoprotein(a). I4399M is located in the protease-like domain of apolipoprotein(a). Compared with noncarriers, carriers of the 4399M risk allele (2.7% of controls) had an adjusted odds ratio for severe CAD of 3.14 (confidence interval 1.51 to 6.56), and had 5-fold higher median plasma lipoprotein(a) levels (P=0.003).
CONCLUSIONS: The LPA I4399M SNP is associated with severe CAD and plasma lipoprotein(a) levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569884     DOI: 10.1161/ATVBAHA.107.141291

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  56 in total

1.  Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.

Authors:  Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss
Journal:  J Lipid Res       Date:  2010-08-16       Impact factor: 5.922

2.  Clinical assessment incorporating a personal genome.

Authors:  Euan A Ashley; Atul J Butte; Matthew T Wheeler; Rong Chen; Teri E Klein; Frederick E Dewey; Joel T Dudley; Kelly E Ormond; Aleksandra Pavlovic; Alexander A Morgan; Dmitry Pushkarev; Norma F Neff; Louanne Hudgins; Li Gong; Laura M Hodges; Dorit S Berlin; Caroline F Thorn; Katrin Sangkuhl; Joan M Hebert; Mark Woon; Hersh Sagreiya; Ryan Whaley; Joshua W Knowles; Michael F Chou; Joseph V Thakuria; Abraham M Rosenbaum; Alexander Wait Zaranek; George M Church; Henry T Greely; Stephen R Quake; Russ B Altman
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

3.  Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study.

Authors:  Mika Kivimäki; Costan G Magnussen; Markus Juonala; Mika Kähönen; Johannes Kettunen; Britt-Marie Loo; Terho Lehtimäki; Jorma Viikari; Olli T Raitakari
Journal:  Int J Epidemiol       Date:  2010-11-14       Impact factor: 7.196

4.  Investigation of associations between ten polymorphisms and the risk of coronary artery disease in Southern Han Chinese.

Authors:  Er-Wen Huang; Long-Yun Peng; Jin-Xiang Zheng; Dan Wang; Xiao-Hong Tan; Zhong-Yi Yang; Xue-Mei Li; Qiu-Ping Wu; Shuang-Bo Tang; Bin Luo; Li Quan; Shui-Ping Liu; Xiao-Shan Liu; Zhao-Hui Li; He Shi; Guo-Li Lv; Jian Zhao; Chao Liu; Jian-Ding Cheng
Journal:  J Hum Genet       Date:  2016-01-07       Impact factor: 3.172

Review 5.  Genome-wide association studies: progress and potential for drug discovery and development.

Authors:  Stephen F Kingsmore; Ingrid E Lindquist; Joann Mudge; Damian D Gessler; William D Beavis
Journal:  Nat Rev Drug Discov       Date:  2008-03       Impact factor: 84.694

Review 6.  Screening for and management of elevated Lp(a).

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

7.  No large-effect low-frequency coding variation found for myocardial infarction.

Authors:  Oddgeir L Holmen; He Zhang; Wei Zhou; Ellen Schmidt; Daniel H Hovelson; Arnulf Langhammer; Maja-Lisa Løchen; Santhi K Ganesh; Ellisiv B Mathiesen; Lars Vatten; Carl Platou; Tom Wilsgaard; Jin Chen; Frank Skorpen; Håvard Dalen; Michael Boehnke; Goncalo R Abecasis; Inger Njølstad; Kristian Hveem; Cristen J Willer
Journal:  Hum Mol Genet       Date:  2014-04-12       Impact factor: 6.150

Review 8.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

9.  Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels.

Authors:  Sonia López; Alfonso Buil; Jordi Ordoñez; Juan Carlos Souto; Laura Almasy; Mark Lathrop; John Blangero; Francisco Blanco-Vaca; Jordi Fontcuberta; José Manuel Soria
Journal:  Eur J Hum Genet       Date:  2008-06-18       Impact factor: 4.246

10.  Genetic variants and their interactions in the prediction of increased pre-clinical carotid atherosclerosis: the cardiovascular risk in young Finns study.

Authors:  Sebastian Okser; Terho Lehtimäki; Laura L Elo; Nina Mononen; Nina Peltonen; Mika Kähönen; Markus Juonala; Yue-Mei Fan; Jussi A Hernesniemi; Tomi Laitinen; Leo-Pekka Lyytikäinen; Riikka Rontu; Carita Eklund; Nina Hutri-Kähönen; Leena Taittonen; Mikko Hurme; Jorma S A Viikari; Olli T Raitakari; Tero Aittokallio
Journal:  PLoS Genet       Date:  2010-09-30       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.